Race Oncology Limited announced that it has appointed Dr James Guy Breitenbucher to its Scientific Advisory Board (SAB). Dr Breitenbucher brings to Race an extensive drug discovery and clinical development history, having spent more than 26 years in scientific leadership positions at a range of large and small pharmaceutical companies, including Johnson & Johnson Pharmaceuticals, Convelo Therapeutics, Libra Therapeutics, Dart Neuroscience, Axys Pharmaceuticals, and Bristol Myers Squibb. Dr Breitenbucher is an exceedingly successful drug discovery and development researcher, having advanced numerous pharmaceutical projects from concept to the clinic.

He is highly skilled in solving complex drug discovery problems, including those surrounding formulations, DMPK, structure biology, pharmacology, biomarkers, IP and safety. While VP of Chemistry at Convelo Therapeutics, he led a major industrial research partnership with Genentech1. At Johnson & Johnson, Guy led multiple pain and CNS drug development programs and delivered 11 compounds into the J&J clinical pipeline, 3 of which are currently in clinical development.

Guy has published more than 59 peer reviewed scientific papers, is a named inventor on 39 patents and has given numerous invited scientific presentations at international conferences. His deep scientific and pharmaceutical industry knowledge will be exceptionally valuable to Race as it advances the development of improved Zantrene® formulations and explores the development of new m6A RNA focused molecules. Dr Breitenbucher joins eminent m6A RNA researcher and discoverer of Zantrene's role as a potent FTO inhibitor, Professor Jianjun Chen of the City of Hope Hospital (USA), on the Race SAB.